European Commission grants Marketing Authorisation for eslicarbazepine acetate as once-daily monotherapy in adults with newly diagnosed partial-onset epilepsy
Bial and Eisai announce that the European Medicines Agency (EMA) has approved eslicarbazepine acetate for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy. It is already indicated in Europe as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.
“We are pleased that adults with partial-onset epilepsy across Europe are now able to benefit from a once-daily monotherapy option that is simple to use, which may optimise their adherence,” comments António Portela, CEO of Bial. “Bial has an ongoing commitment to all people living with epilepsy and we look forward to continuing to work with the epilepsy community to bring this new indication to patients.”
The continued development of eslicarbazepine acetate underscores Bial’s and Eisai’s commitment to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy.
Epilepsy is one of the most common neurological conditions in the world, affecting approximately 6 million people in Europe, and an estimated 50 million people worldwide. Epilepsy is a chronic disorder of the brain that affects people of all ages. More information here.